Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme

Journal of Clinical Pharmacology

Volumn 45, Issue 3, 2005, Pages 299-312

  Miles, Dale R ^a   Smith, Jennifer A ^a   Phan, See Chun ^a   Hutcheson, Sammy J ^b   Renschler, Markus F ^a   Ford, Judith M ^c   Boswell, Garry W ^a  

^a PHARMACYCLICS INC   (United States)

^b IQVIA   (United States)

^c UCLA MEDICAL CENTER   (United States)

Author keywords

Brain metastases; Glioblastoma multiforme; Motexafin gadolinium; Population pharmacokinetics

Indexed keywords

ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; CARBAMAZEPINE; CREATININE; CYTOCHROME P450; DIPHENHYDRAMINE; DOCUSATE SODIUM; FAMOTIDINE; FLUCONAZOLE; GADOLINIUM TEXAPHYRIN; GRANISETRON; IBUPROFEN; LORAZEPAM; METOCLOPRAMIDE; NYSTATIN; OMEPRAZOLE; ONDANSETRON; OXYCODONE; PARACETAMOL; PHENYTOIN; PROCHLORPERAZINE; RANITIDINE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN TUMOR; CANCER RADIOTHERAPY; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; GLIOBLASTOMA; HUMAN; INFECTION; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; POPULATION RESEARCH; SEIZURE; VOMITING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTICONVULSANTS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CLINICAL TRIALS; CREATININE; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; METABOLIC CLEARANCE RATE; METALLOPORPHYRINS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; PHENYTOIN; SEX FACTORS; SOFTWARE;

EID: 16844366940     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004271946     Document Type: Article

References (17)

1. Mody TD, Fu L, Sessler JL. Texaphyrins: synthesis and development of a novel class of therapeutic agents. In: Karlin KD, ed. Progress in Inorganic Chemistry. New York: John Wiley; 2001:551-598.
2. Mehta MP, Rodrigus P, Terhaard C, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529-2536.
3. Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 2002;20:3445-3453.
4. Magda D, Lepp C, Gerasimchuk N, et al. Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species. Int J Radiat Oncol Biol Phys. 2001;51:1025-1036.
5. Rosenthal DI, Nurenberg P, Becerra CR, et al. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res. 1999;5:739-745.
6. Carde P, Timmerman R, Mehta MP, et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol. 2001;19:2074-2083.
7. Boeckmann AJ. NONMEM Users Guide: Part V. Introductory Guide. San Francisco: NONMEM Project Group, University of California at San Francisco; 1992.
8. Mizuta E, Tsubotani A. Preparation of mean drug concentration-time curves in plasma: a study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull (Tokyo). 1985;33:1620-1632.
9. Lacey LF, Keene ON, Pritchard JF, Bye A. Common noncompartmental pharmacokinetic variables: are they normally or log-normally distributed? J Biopharm Stat. 1997;7:171-178.
10. Julious SA, Debarnot CA. Why are pharmacokinetic data summarized by arithmetic means? J Biopharm Stat. 2000;10:55-71.
11. SAS Institute. SAS Language and Procedures, Version 6. Cary, NC: SAS Institute; 1989.
12. Vozeh S, Maitre PO, Stanski DR. Evaluation of population (NONMEM] pharmacokinetic parameter estimates. J Pharmacokinet Biopharm. 1990;18:161-173.
13. Gordon T. Factors associated with serum alkaline phosphatase level. Arch Pathol Lab Med. 1993;117:187-190.
14. Wilding P, Rollason JG, Robinson D. Patterns of change for various biochemical constituents detected in well population screening. Clin Chim Acta. 1972;41:375-387.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
16. Nagaraja NV, Park YJ, Jeon S, Sands CD, Derendorf H. Population pharmacokinetics of digoxin in Korean patients. Int J Clin Pharmacol Ther. 2000;38:291-297.
17. Sheiner L, Beal S. A note on confidence intervals with extended least squares parameter estimates. J Pharmacokinet Biopharm. 1987;15:93-98.